NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series Developed by Aexon Labs
Friday, October 31, 2025
NLS Pharmaceutics Ltd, a Swiss clinical-stage biopharmaceutical company specialising in central nervous system (CNS) and neurodegenerative disorders, together with Aexon Labs, a biotechnology company focused on next-generation CNS therapeutics, has expanded its DOXA platform with the AEX-6xx series. This new generation of small molecules is designed to target arousal stability, cognition, and neuroprotection.
Among the lead compounds, AEX-635 has shown the ability to modulate Multidrug Resistance-Associated Protein 1 (MRP1), which may enhance neuroprotective effects and improve CNS drug bioavailability. This mechanism could be particularly beneficial in conditions driven by oxidative stress, such as Parkinson’s disease and gliopathies.
The AEX-6xx series is based on a novel class of dihydroquinazoline and dihydrobenzothiazine derivatives. The DOXA platform combines dual orexin receptor agonism (OX1R/OX2R) with cathepsin H (CTSH) inhibition, addressing key pathways related to sleep-wake balance, motivation, and neuronal resilience.
The expansion of this platform strengthens the position of NLS Pharmaceutics and Aexon Labs in the field of multi-target CNS drug development. It also supports the mission of NewCelX, the combined company that will form after the planned merger of NLS Pharmaceutics and Kadimastem Ltd. The merger aims to integrate neuroscience and cell therapy innovation to develop advanced treatments for complex neurological and metabolic disorders.
Source: prnewswire.com
